Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
Authors:
- 11 March 2021
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (9) , 5417-5423
Abstract
Purpose Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in cancer patients. However, the association of VTE with immunotherapy remains poorly defined. We therefore evaluated the frequency of VTE in patients receiving immunotherapy and tried to determine predisposing factors. Methods A total of 133 adult metastatic cancer patients treated with immunotherapy for any cancer between were included. Baseline demographics, ECOG performance status, type of tumors, and baseline blood count parameters were recorded. Possible predisposing factors were evaluated with univariate and multivariate analyses. Results The median age was 60 (interquartile range (IQR) 48–66) years, and the median follow-up was 10.1 (IQR 5.8–18.5) months. Renal cell carcinoma (26.3%) and melanoma (24.1%) were most common diagnoses. Fifteen patients (11.3%) had an episode of VTE. Most of the VTEs were diagnosed as pulmonary emboli (10/15; 67%). Eighty percent (12/15) of these VTE cases were detected incidentally. Patients with a baseline ECOG performance status of 1 or more (29.3% of patients) had a significantly increased risk of venous thrombosis (ECOG ≥1 vs. 0, HR: 3.023, 95% CI: 1.011–9.039, p=0.048). Other factors, including patient age, tumor type, body mass index, baseline thrombocyte, neutrophil, and lactate dehydrogenase levels were not significantly associated with VTE risk. Conclusions In this study, we observed VTE development in more than 10% of immunotherapy-treated patients and increased VTE risk in patients with poorer ECOG status. With the asymptomatic nature of VTEs in most cases, a high index of suspicion level for VTE is required in patients treated with immunotherapy.Keywords
This publication has 36 references indexed in Scilit:
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratioInternational Journal of Cancer, 2014
- Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected eventsActa Radiologica, 2014
- Thrombosis in ovarian cancer: a case control studyBritish Journal of Cancer, 2014
- Venous thromboembolism and prognosis in cancerThrombosis Research, 2010
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage studyJournal of Thrombosis and Haemostasis, 2006
- Cancer and venous thromboembolismThe Lancet Oncology, 2005
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987